Friday, November 13, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Software Vendors Cut Guidance as Demand Compresses

Salesforce is down 43% year-to-date and Adobe has fallen 49% year-over-year as enterprise AI software vendors slash guidance. Accenture explicitly cited 'AI demand compression' as buyers pause spending pending clearer ROI evidence. Analysts expect continued multiple compression at IBM, Infosys, and Cognizant over the next one to two quarters.

LM Salvado
LM Salvado

June 25, 2026

Salesforce -43%, Adobe -49%: Enterprise AI Software Vendors Cut Guidance as Demand Compresses
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Accenture has cut guidance, explicitly citing "AI demand compression."1 The enterprise AI application layer is hitting a demand ceiling.1 The clustering of underperformance across vendors is not coincidental — it signals a structural problem at the buyer level, not individual execution failures.

Enterprise technology buyers spent 2024 and 2025 funding AI pilots. Finance teams are now demanding proof of returns before approving renewals or new projects. Without demonstrated ROI, procurement cycles are extending and software upsell motions are stalling.

Accenture's language carries weight. As the largest IT services firm by revenue, its explicit reference to "AI demand compression" in a guidance cut is a direct signal that enterprise AI project pipelines are not converting at the pace revenue models assumed.1 The consulting-to-software flywheel that underpinned AI revenue projections has slowed.

The pressure is unlikely to stay contained. IBM, Infosys, and Cognizant draw AI consulting revenue from the same enterprise buyer base.1 If Accenture is compressing, those firms face the same headwinds in coming quarters.

For equity investors, the repricing reflects a market revising one core assumption: that AI would drive immediate, durable upsell in enterprise software.

Enterprise AI budgets are not disappearing. They are being redirected — away from application-layer software where margin expansion was priced in, and toward infrastructure and foundational model spend where ROI is more tangible. Vendors unable to show measurable cost reduction or revenue lift in live deployments are the ones absorbing the cuts.

The next one to two quarters will determine whether current guidance reductions mark a reset or the opening of a longer correction cycle.1

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com